Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. - Wikidata - wikimedia - TriplyDB

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.

http://www.wikidata.org/entity/Q42667417

about

Pulmonary arterial hypertension: a comparison between children and adults Treprostinil for the treatment of pulmonary arterial hypertension Bloodstream infections in patients given treatment with intravenous prostanoids.Pulmonary Hypertension in Children.Pulmonary hypertension: diagnosis and management A systematic review of transition studies of pulmonary arterial hypertension specific medications Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Experiences with treprostinil in the treatment of pulmonary arterial hypertension.Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.Diagnosis and management of pulmonary arterial hypertension Prostanoid therapies in the management of pulmonary arterial hypertension.Overview of current therapeutic approaches for pulmonary hypertension.Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension.Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension Update in pulmonary hypertension 2005.Optimizing the 6-min walk test as a measure of exercise capacity in COPD.Treatment of pulmonary hypertension Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.Updated evidence-based treatment algorithm in pulmonary arterial hypertension.Expert opinion on available options treating pulmonary arterial hypertension.Medical therapy for pulmonary arterial hypertension.Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.Emerging drugs for pulmonary hypertension.Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.Advances in therapies for pediatric pulmonary arterial hypertension.Prostacyclin therapy for pulmonary arterial hypertension.The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.Treatment of pulmonary arterial hypertension with targeted therapies.Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.Inhaled treprostinil for the treatment of pulmonary arterial hypertension.Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.New pharmacotherapies for pulmonary hypertension: where do they fit in?

P2860

Q27687320-FDFBE041-B4AC-4DB7-8E58-1A0BA59F3347 Q28281899-43CD3932-FBBE-4609-8853-C6095EBFF782 Q30228937-D7977674-7646-436A-8E3E-264EE8BE04B1 Q30248871-CE65543E-9A05-4F87-83E4-45EBAA37DD2F Q33157071-D145063A-6843-483D-96A9-980DB4D21005 Q33788548-EE22445A-31EE-4DFF-8C1E-A6B62CE4991B Q33965898-CC5D463A-5F09-4014-87BD-7B0011A3F0A7 Q33982476-4245A7C2-7932-485F-B9B0-EE8C4637D86A Q34064492-12DB4830-10E4-45A0-9662-8C62747EED3C Q34088723-FC41E581-4302-4DDB-8898-A8A1F78C937F Q35222937-48DAA5FA-1BE3-4FE6-B118-BF28BCC82B3D Q35284318-DE9E4A1D-4388-4909-8684-7CB64350C606 Q35412362-8C6B8A70-972E-4D6B-B5C3-0359AD8C30A5 Q35987352-AF9C04CA-E2F6-41FB-BA0B-67C193DA03DB Q36016519-295E81A8-4773-4B13-A776-FA97D72D70EE Q36142916-0510381E-D005-4FAB-8868-FE11C5459D5A Q36325779-5505BA7A-A467-4BF5-A718-BE24A6755007 Q36403168-A1959F80-9134-4871-9952-619BD1594DD4 Q36447382-92DD008A-FEC5-433C-B966-9C036E402B62 Q36577681-C4C7DBE3-7553-4C50-8ABC-5033815246E4 Q36681338-50C70636-1F47-47C3-A7B2-EBA3A7AEBBB4 Q36763080-CEC2F357-1852-4507-9E15-552BD68B8750 Q36777766-D5009D89-99C1-44CB-9A30-329E3B23D7C8 Q36939543-10C78F5B-87B1-4546-AC6A-63AAA44449C1 Q36967262-C402A2D0-4402-4243-A297-1E801A1AF120 Q37030844-EF68BB01-74D8-4C1B-B417-5A3C46CE1137 Q37139801-4122CE31-CC31-427E-8296-523DAE009D8A Q37679940-99885FCE-F8E5-4A79-ADEC-A5D06EF92CED Q37705261-C05D11DA-950A-4F8B-A02B-15BDB87CFB3A Q37755020-5667B6B2-3530-4FDE-844E-957A747CC9DC Q37789151-3469682B-A508-4C1B-AB9E-7C14763AF84E Q37837276-0D0D9EF0-696A-41E1-85F4-9FBBEF8E0F88 Q37879213-FA01CB7E-3798-4202-91A6-92CC278519B1 Q37902509-420DE1DA-11FD-4BD6-AEBC-3CE4E699390F Q37944298-663B2717-2CD6-41FB-9BB1-155F37F4CCAB Q38025723-9311CE9A-DE19-4BAA-9DF0-74832046F130 Q38027095-BE271215-6B18-48A9-BFB0-E57167B28AB0 Q38066529-AEDADD3B-5C28-4AB7-BE5D-BFFD8C782CCA Q38077796-4192E8BB-1768-48FD-B41F-7BA2B84A962F Q38258961-FBD535F0-3DEE-4EB3-9DFA-A32983E4990A

P2860

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.

http://www.wikidata.org/entity/Q42667417

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Transition from intravenous ep ...... nil in pulmonary hypertension.

@en

Transition from intravenous ep ...... nil in pulmonary hypertension.

@nl

type

label

Transition from intravenous ep ...... nil in pulmonary hypertension.

@en

Transition from intravenous ep ...... nil in pulmonary hypertension.

@nl

prefLabel

Transition from intravenous ep ...... nil in pulmonary hypertension.

@en

Transition from intravenous ep ...... nil in pulmonary hypertension.

@nl

P1433

Q42667417-8C6BEF6B-056F-422C-BE1C-5F124441DE45

P1476

Q42667417-1BCA3774-6F12-4863-B67F-9D3F5FDA0A4D

P2093

Q42667417-27AF37B2-0504-4E3D-B7E3-F914318F1E1A

Q42667417-4451450A-B83B-4348-A5F7-7015BB80ABD3

Q42667417-550A148D-193C-43C7-A276-EB2EF6413453

Q42667417-6BCF849E-E1E4-463B-B310-644C91AF921C

Q42667417-D7B5650C-201D-4750-A64F-722A0FAD70CA

Q42667417-D9AFE05F-BCE1-44AC-93D4-2FF65D266C3C

Q42667417-FAAC79D3-574C-4F1C-94B5-EE80D40F5A49

P2860

Q42667417-2875BECD-4E1D-42FA-B435-F3B8110A014B

Q42667417-3D4C9F2A-1AA9-48B3-B922-A40A71D85695

Q42667417-499D8701-926F-4869-AC94-8AF3CDDD5ED4

Q42667417-65C0B7D8-333B-4414-9868-126A75E8F4AB

Q42667417-AA761F0B-9BDB-43EC-A0ED-2E3314636EAC

Q42667417-BF46AEF6-67CB-44AE-9BC0-DD745DE25B02

Q42667417-CE541B46-3025-40D1-875B-B2CEA31C5594

Q42667417-D8A11779-BCD3-4FF0-B51B-3B94A89AA758

Q42667417-F41B4DB3-3FE4-4F6B-932E-F40051976EFF

P304

Q42667417-63D9F3E1-F133-49BB-BF94-F66CEE302FA4

P31

Q42667417-02E690EB-247C-4EAC-9EA1-661D8BE5501D

P356

Q42667417-BFAE23B2-2B56-4C7F-BA51-509E8C34E21A

P407

Q42667417-1C4B358C-3825-4A79-B94D-C2E58E46E6CC

P433

Q42667417-E8484CA8-A352-4D33-9C85-B0C7776D2AC0

P478

Q42667417-B367E6D0-DC2D-4DC3-8851-E68DF7FC486F

P577

Q42667417-4371CBD9-E267-4CF0-8C11-65DB230E2113

P698

Q42667417-2F2035F3-2B26-42EB-A4E7-C6E63607B2DE

P356

RCCM.200505-766OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Transition from intravenous ep ...... nil in pulmonary hypertension.

@en

P2093

Abigail Krichman

http://www.w3.org/2001/XMLSchema#string

Allison C Widlitz

http://www.w3.org/2001/XMLSchema#string

Mardi Gomberg-Maitland

http://www.w3.org/2001/XMLSchema#string

Raymond L Benza

http://www.w3.org/2001/XMLSchema#string

Robyn J Barst

http://www.w3.org/2001/XMLSchema#string

Vallerie V McLaughlin

http://www.w3.org/2001/XMLSchema#string

Victor F Tapson

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Treatment of pulmonary hypertension secondary to connective tissue diseases.

The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected]

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

P304

1586-1589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200505-766OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16151039

http://www.w3.org/2001/XMLSchema#string